Newsroom

A scientist operates a bioreactor in the lab

News

The DZIF flagship project PANTIPA has reached an important milestone. Following successful preclinical work at the University Hospital Cologne and the Helmholtz Centre for Infection Research (HZI), the project is now entering the next stage of development, including process development and GMP-compliant manufacturing of a monoclonal antibody targeting Pseudomonas aeruginosa. The Celonic Group has been selected as a partner for process development and production. The goal of PANTIPA is to advance an innovative antibody therapy to the clinical trial stage, thereby creating new treatment options for patients with severe infections.

25.08.2026

HZI Campus

Two people in the lab, smiling at the camera

News

The SARS-CoV-2 coronavirus is constantly mutating. As a result, vaccines become less effective and need to be regularly adapted. This was the case in 2025 with the JN.1 variant. An interdisciplinary team from Hannover and Göttingen has now investigated how the immune system responds to adapted vaccines. The findings were published in Nature Communications.

17.08.2026

TWINCORE

Two petri dishes containing myxobacteria are held aloft, one in each hand

News

Most antibiotics used clinically are based on natural compounds produced by bacteria and other microorganisms. At the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), researchers are using soil-dwelling myxobacteria as a source of new active ingredients. They are able to discover new active compounds primarily in bacteria that have not yet been extensively studied. Through decades of work, a HIPS research team has significantly expanded the biological diversity of myxobacteria. They are now making these microorganisms and their genetic data available to the entire research community, as they provide the basis for the discovery of new bioactive compounds. The researchers published their findings in the journal Advanced Science.

12.08.2026

HIPS

News

At first glance, mucus sounds more unpleasant than essential. In fact, it forms an important protective layer on our mucous membranes: It transports dirt, bacteria, and viruses out of the body and makes it difficult for pathogens to penetrate our cells in the first place. Prof. Christian Sieben, head of the research group “Nano Infection Biology” at the Helmholtz Centre for Infection Research (HZI), is studying this crucial moment in an infection in great detail. Using state-of-the-art microscopy, he observes individual virus particles and investigates how they interact with our cells. In this episode of InFact, he explains how respiratory viruses overcome our natural barriers and why influenza viruses in particular have significant pandemic potential.

23.07.2026

HZI Campus

A view inside a laboratory; two hands wearing blue gloves working with a pipette

News

Bacteria have spent decades evolving resistance to virtually every antibiotic we have thrown at them. To stay ahead, new drugs must hit targets that existing antibiotics have never touched. A research team at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now developed a series of synthetic drug candidates that do exactly that: By blocking an essential molecular supply system, these molecules cut off the bacteria's essential vitamins supply and starve them to death. The team published its findings in two studies back to back in the Journal of Medicinal Chemistry.

21.07.2026

HIPS

Macrophages under an electron microscope

News

Macrophages are considered the “scavenger cells” of the immune system, but some pathogens exploit these very cells as hiding places. Researchers from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg and Philipps-Universität Marburg have now discovered a mechanism that helps immune cells to balance their response to infection: a long non-coding ribonucleic acid called SAILR, which acts as an apoptosis regulator. The findings were published recently in the journal PNAS.

20.07.2026

HIRI

HZI in the media

international institutions including Trinity College Dublin, the Helmholtz Institute for One Health, Université Paris 1 Panthéon-Sorbonne,

02.09.2026

EurekAlert!

... die präzise Zerspanung großer Bauteile. Das Helmholtz-Zentrum für Infektionsforschung in Braunschweig und die Medizinische Hochschule ...

01.09.2026

Regionalupdate.de

... zunehmen. Mit der Gründung des HIOH im Jahr 2021 als Standort des Braunschweiger Helmholtz-Zentrums für ...

31.08.2026

Management & Krankenhaus

Wie man sich mit Mpox anstecken kann und warum sich Personen mit häufig wechselnden Sexpartnern impfen lassen sollten.

28.08.2026

Apotheken Umschau

... des neuen Forschungsgebäudes des Helmholtz-Instituts für One Health (HIOH) in Greifswald (Landkreis Vorpommern-Greifswald) gelegt

. ...

28.08.2026

Tagesschau

How Bacteria Develop Resistance to Antisense Antibiotics—and How Future Therapies Can Be Made Less Susceptible to It

28.08.2026

Bionity.COM

Infection Research; the RESIST Cluster of Excellence; and the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg has

27.08.2026

Phys.org

... Arbeiten am Universitätsklinikum Köln und am Helmholtz-Zentrum für Infektionsforschung startet nun die Entwicklung und GMP- ...

26.08.2026

healthcare-in-europe.com

Infos: Herpesviren – Eine große Familie Helmholtz Zentrum für Infektionsforschung www.helmholtz-hzi.de/wissen/wissensportal/ ...

25.08.2026

SWR4 Rheinland-Pfalz

An einer weiteren Station veranschaulicht das Helmholtz-Institut für Pharmazeutische Forschung, wie die Entwicklung neuer ...

25.08.2026

MSN Deutschland

Technologien“ im HUMAN-Projekt am Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig . Im Mittelpunkt ihrer Arbeit steht ...

23.08.2026

Regional Heute

... Medizinischen Hochschule Hannover (MHH) und des Helmholtz-Zentrums für Infektionsforschung (HZI). Dafür setzten die Forschenden sechs ...

19.08.2026

Pharmazeutische Zeitung

Register now for the HZI newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.